- Exchange: London
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for Shire PLC (SHP)
| Open: | 2,079.000 | Day's Range: | 2,061.000 - 2,090.000 | Volume: | 1,605,148 |
|---|---|---|---|---|---|
| Previous Close: | 2,050.000 | 52wk Range: | 1,682.000 - 2,173.000 | 1-Yr Rtn: | +9.52% |
Key Statistics for SHP
| Current P/E Ratio (ttm) | 30.9002 |
|---|---|
| Estimated P/E(12/2013) | 14.1480 |
| Relative P/E vs. UKX | 1.8075 |
| Earnings Per Share (USD) (ttm) | 1.0286 |
| Est. EPS (USD) (12/2013) | 2.2470 |
| Est. PEG Ratio | 1.5746 |
| Market Cap (M GBP) | 11,559.66 |
| Shares Outstanding (M) | 554.15 |
| 30 Day Average Volume | 2,167,854 |
| Price/Book (mrq) | 4.6433 |
| Price/Sale (ttm) | 3.8079 |
| Dividend Indicated Gross Yield | 0.53% |
| Cash Dividend (GBp) | 9.3900 |
| Last Dividend | 03/06/2013 |
| 5 Year Dividend Growth | 20.60% |
| Next Earnings Announcement | 07/25/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for SHP
Company Profile & Key Executives for SHP
Shire PLC markets, licenses and develops prescription medicines. The Group focuses its operations on attention deficit and hyperactivity disorders, human genetic therapies, gastrointestinal, and renal diseases.
| Flemming OrnskovChief Executive Officer | Michael Yasick "Mike"Interim President |
| Graham C HetheringtonChief Financial Officer | Jeffrey M Jonas "Jeff"President:Regenerative Medicine |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
SHP News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page